Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Federica Zamagni has a total of 283 co-authors. Here are the top co-authors by number of shared publications:

  • Lauro Bucchi

    Emilia-Romagna Cancer Registry, Romagna Cancer Institute, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) Dino Amadori, Meldola, Forlì, Italy

    15 shared publications
  • Silvia Mancini

    Emilia-Romagna Cancer Registry, Romagna Cancer Institute, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) Dino Amadori, Meldola, Forlì, Italy

    14 shared publications
  • Fabio Falcini

    Emilia-Romagna Cancer Registry, Romagna Cancer Institute, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) Dino Amadori, Meldola, Forlì, Italy; Cancer Prevention Unit, Local Health Authority, Forlì, Italy

    7 shared publications
  • Emanuele Crocetti

    Romagna Cancer Registry, IRCCS, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), Meldola, Italy

    6 shared publications
  • Fabio Falcini

    Romagna Cancer Registry, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, 47014 Meldola, Italy

    6 shared publications
  • Rosa Vattiato

    Emilia-Romagna Cancer Registry, Romagna Cancer Institute, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) Dino Amadori, Meldola, Forlì, Italy

    6 shared publications

Latest Publications

  • Open Access

    Prevalence and Cure of Primary Liver Cancer in Italy by Histologic Type

    by Lauro Bucchi, Stefano Ferretti, Federica Toffolutti, Ugo Fedeli, Silvia Mancini, Federica Zamagni, Fabiola Giudici, Laura Botta, Manuel Zorzi, Ettore Bidoli, et al.

    Background/Objectives: In Italy, one- and five-year survival of primary liver cancer patients have increased in recent decades and were higher after hepatocellular carcinoma (HCC) than after intrahepatic cholangiocarcinoma (ICC). This study aimed to estimate the complete prevalence and cure indicators (long-term survival) after liver cancer diagnosis by histologic type. Methods: Data from 31 Italian cancer registries, covering 28,057,000 residents (47% of the population), were included. The complete prevalence was calculated in 2018. The mixture-cure model was used to estimate the cure fraction (CF, proportion of newly diagnosed patients with the same life expectancy as the general population), the cure prevalence (prevalent patients who will not die as a result of cancer) and the life expectancy of fatal cases (LEF). Results: In 2018, 31,723 Italians (53 per 100,000) lived after a liver cancer diagnosis. Among them, the cure prevalence was 23.3% for HCC and 40.3% for ICC. The CF remained <10% for cases diagnosed in recent decades. Higher and rising CF rates were observed between 2005 and 2015 only among patients with HCC aged <45 years (2% of all cases), with an increase from 13% to 22% in men and from 19% to 29% in women, and among patients aged 45–54 years (8% of all cases), with an increase from 7% to 15% in men and from 11% to 19% in women. The LEF for HCC in 2015 was 29 months for both sexes, an 8-month increase since 2005. Conclusions: No substantial advantage nor favourable trends in the CF was apparent for older patients with HCC as compared to those with ICC, with some progresses for the small age groups of <45 years. A clear-cut increase in CF of patients with HCC aged under 55 years occurred in the 2010s decade, with no changes for older patients. This was accompanied by an increase in the LEF. Although limited by a considerable proportion of liver cancers of unspecified histologic type, the cure indicators presented here may help monitor the long-term effects of therapeutic advances and of surveillance programmes for people with cirrhosis and HCV infection.

  • Open Access

    Mid-term effects of faecal immunochemical test screening on colorectal cancer incidence by tumour site

    by Lauro Bucchi, Silvia Mancini, Flavia Baldacchini, Alessandra Ravaioli, Orietta Giuliani, Rosa Vattiato, Federica Zamagni, Debora Canuti, Priscilla Sassoli de Bianchi, Fabio Faccini, et al.

  • Open Access

    Opportunistic and Organized Cervical Cancer Screening: Impact on Lesion Severity and Surgical Outcomes in 9830 Cervical Conizations

    by Mario Preti, Niccolò Gallio, Silvano Costa, Fulvio Borella, Paola Armaroli, Pedro Vieira-Baptista, Federica Zamagni, Federica Bevilacqua, Paola Garutti, Daniele Tota, et al.

    Objectives: To assess the impact of organized (OgS) versus opportunistic screening (OpS) on grade, extent, and surgical management of cervical lesions, and to evaluate human papillomavirus (HPV)-based versus cytology-based screening within OgS. Methods: This retrospective study analyzed 9830 women undergoing conization (1992–2021). Data included screening modality, histology, cervical intraepithelial neoplasia grade 3 (CIN3) linear extension, and cone volume. Statistical analysis employed chi-square test, Student’s t-tests, Cochran–Armitage test for trend, and Firth’s penalized multivariate logistic regression to identify independent predictors of invasive disease. Results: Of 9830 patients, 5097 (52%) were referred from OgS and 4733 (48%) from OpS. OgS patients were significantly older (40.0 vs. 37.0 years; p < 0.001). In the final decade, OgS achieved a significantly lower rate of invasive carcinomas compared to OpS (1.1% vs. 2.7%; p < 0.001). Mean CIN3 extension and cone volume were significantly lower in OgS (6.5 mm; 1150 mm3) than in OpS (7.1 mm; 1580 mm3; p < 0.001). Within OgS, HPV-detected CIN3 lesions were smaller than cytology-detected ones (5.9 vs. 6.4 mm; p < 0.001). Long-term analysis showed a borderline downward trend in invasive cancer for OgS (p = 0.089), whereas OpS remained stable at higher risk levels. Multivariate analysis confirmed the screening model as an independent predictor of invasiveness: OpS was associated with a two-fold increased risk of invasive cancer compared to OgS (adjusted odds ratio: 1.99; 95% confidence interval: 1.41–2.83; p < 0.001). Conclusions: OgS identifies high-grade precancers earlier and with smaller excisional requirements. OpS is associated with significantly higher invasive cancer rates and larger conizations. Multivariate data reinforce OgS as a superior framework, effectively halving the risk of invasive disease compared to OpS.


  • Open Access

    Human Papillomavirus Testing and Size of CIN3: Implications for the Risk of Microinvasive Cervical Carcinoma

    by Mario Preti, Annibale Biggeri, Guglielmo Ronco, Maria Kyrgiou, Raffaella Rizzolo, Paola Armaroli, Niccolò Gallio, Murat Gultekin, Federica Zamagni, Silvano Costa, et al.

    (1) Background/Objectives: Human papillomavirus (HPV) testing is hypothesised to detect cervical intraepithelial neoplasia grade 3 (CIN3) earlier than cervical cytology, which could translate into several clinical benefits. This study aimed to confirm that HPV testing detects CIN3 lesions of smaller size (or linear extension) and to assess whether this is associated with a decreased risk of stromal microinvasion (≤3 mm) (microinvasive or stage IA1 cervical carcinoma). (2) Methods: The study was conducted in a referral centre for cervical pathology in Italy. Eligible were 3744 patients aged 30–64 years who underwent local excision of the cervix between 1992 and 2021 and were diagnosed with CIN3, with or without microinvasion. Data were analysed using logistic and multinomial regression models. (3) Results: Overall, 1156 (30.9%) CIN3 cases were detected by the HPV test, and 2588 (69.1%) by cervical cytology. The lesion size was smaller in HPV test-detected CIN3 (median, 6 mm; interquartile range (IQR), 4–8 mm) than in cytology-detected CIN3 (median, 7 mm; IQR, 5–9 mm; p < 0.001). HPV test-detected CIN3 was over 50% less likely to have a size >6 mm combined with massive glandular crypt involvement. Stromal microinvasion occurred in 20/1156 (1.7%) HPV test-detected lesions versus 87/2588 (3.4%) cytology-detected lesions (p = 0.006), corresponding to an approximately 50% lower age-adjusted risk. The smaller size of HPV test-detected CIN3 and its lower degree of glandular crypt involvement interacted additively, rather than multiplicatively, in reducing the risk of stromal microinvasion. Over 46% of the association between detection mode and stromal microinvasion was explained by the size/involvement composite variable. (4) Conclusions: HPV testing detects CIN3 lesions of smaller size than cervical cytology. HPV test-detected CIN3 has a lower risk of stromal microinvasion. This association is mediated to a substantial extent by the smaller lesion size and the less extensive glandular crypt involvement, which interact in an additive manner. These findings may have other important clinical implications. First, the prevalence of disease persistence after treatment may decrease. Second, smaller lesions are likely to be treated with more limited excisions. Third, this may contribute to a lower rate of preterm birth in subsequent pregnancies.


  • Open Access

    Trends in Survival and Cure Indicators of Thin and Thick Cutaneous Malignant Melanoma in Italy

    by Silvia Mancini, Federica Toffolutti, Federica Zamagni, Lauro Bucchi, Emanuele Crocetti, Fabiola Giudici, Francesca Bella, Andrea Benedetto, Ettore Bidoli, Simona Carone, et al.

    Background: In Italy, cure indicators of cutaneous malignant melanoma according to Breslow tumour thickness have never been assessed. Objectives: To evaluate the time trend in 1‐year net survival (NS), 5|1‐year conditional NS (CNS) and cure fraction (CF). Methods: Data from 10 cancer registries and 13,377 patients aged 15–74 years were used. Five|1‐year CNS was defined as the probability of surviving 5 years given that the patient has survived 1 year. CF was defined as the proportion of patients with the same life expectancy as the general population. One‐year NS and 5|1‐year CNS were contrasted between 2013–2017 and 2003–2007, and CF between 2015 and 2005. Results: For lesions up to 4 mm thick, 1‐year NS reached a level > 98.0%. In 2013–2017, 5|1‐year CNS was above 90% for men and women with lesions up to 2.0 mm thick and increased markedly for men with lesions > 2.0–4.0 mm thick (65.1% to 82.4%) and > 4.0 mm thick (57.6% to 69.4%). The CF of patients with a melanoma ≤ 1.0 mm thick was approximately 100% in both sexes, and nearly doubled from 2005 to 2015 (28% to 54%) for men aged 55–74 years with a melanoma > 4.0 mm thick. Conclusions: Patients with a melanoma ≤ 1 mm thick have the same life expectancy as the general population. The increase in the CF of men with thick lesions supports the hypothesis that novel therapies, approved in Italy since 2013, offer the possibility of cure.


  • Open Access

    Melanoma in Primary Care: A Narrative Review of Training Interventions and the Role of Telemedicine in Medical Education

    by Ignazio Stanganelli, Edoardo Mora, Debora Cantagalli, Serena Magi, Laura Mazzoni, Matelda Medri, Cesare Massone, Davide Melandri, Federica Zamagni, Ines Zanna, et al.

    General practitioners play a crucial role in the early detection and prevention of cutaneous melanoma. However, structured training on skin cancer diagnosis and management is often lacking. This narrative review aims to map the current educational interventions for general practitioners focused on melanoma, assess their methodological approaches and outcomes, and explore the contribution of e-learning and telemedicine in medical education. A comprehensive literature search identified 54 relevant studies published between 1 January 1995 and 31 December 2024. Data were extracted and categorized by topics covered, training methodology, interactivity, and clinical outcomes. Training programs varied widely in duration, delivery, and content. Interventions that integrated dermoscopy and interactive methodologies demonstrated improved diagnostic accuracy and clinical impact. E-learning, particularly asynchronous models, emerged as a flexible and effective modality, although few studies evaluated long-term retention or clinical practice changes. Educational programs tailored to general practitioners and enriched with dermoscopy and telemedicine tools show promise in improving melanoma detection and care. Structured, interactive, and blended/hybrid learning models should be prioritized to support effective primary and secondary prevention.

  • Open Access

    Evaluating perineural invasion severity in head and neck cutaneous squamous cell carcinomas to refine prognostic accuracy: A retrospective case-control study

    by Filippo Nozzoli, Silvia Mancini, Andrea Ambrosini-Spaltro, Emilia Crisanti, Luca Riccioni, Giovanni De Luca, Annarita Lombardi, Fabio Falcini, Rosa Vattiato, Federica Zamagni, et al.


  • Open Access

    Upfront intensive treatment analysis of the Italian Cohort Study on FLT3‐mutated AML patients (FLAM): The impact of a FLT3 inhibitor addition to standard chemotherapy in the real‐life setting

    by Jacopo Nanni, Irene Azzali, Cristina Papayannidis, Antonino Mulè, Ernesta Audisio, Maria Paola Martelli, Barbara Scappini, Patrizia Chiusolo, Benedetta Cambò, Anna Candoni, et al.

    Background: The addition of a FLT3 inhibitor (FLT3i) to standard chemotherapy to treat fit newly diagnosed (ND) patients with FLT3‐mutated acute myeloid leukemia (AML) represents the standard of care resulting from clinical trial results. However, evidence regarding FLT3i adoption in routine clinical practice is still scarce.Methods: Clinical data are reported from 394 ND patients with FLT3‐mutated AML enrolled in the retrospective observational Italian Cohort Study on FLT3‐mutated patients with AML and treated with an upfront intensive regimen with (FLT3i group, n = 92) or without (CT group, n = 302) the addition of a FLT3i.Results: With a median follow‐up time of 34.5 months, an effectiveness benefit obtained by FLT3i incorporation both in terms of overall survival (median, 34.9 in the FLT3i vs 12.7 months in the CT group, p < .01) and relapse‐free survival (median, 18.9 in the FLT3i vs 7.6 months in the CT group, p = .01) was documented, with a higher composite complete remission rate (75.4% in the FLT3i vs 62.4% in the CT group, p = .052). FLT3i benefit seemed to be independent from the transplant rate.Conclusions: In conclusion, the benefit of FLT3i addition to upfront intensive treatment in newly diagnosed FLT3‐mutated AML patients was confirmed in a large, real‐life cohort study.

  • Open Access

    Estimates of the burden of skin melanoma in Italy: update to 2024

    by Emanuele Crocetti, Federica Zamagni, Fabio Falcini, Rosa Vattiato, Flavia Baldacchini, Chiara Balducci, Orietta Giuliani, Silvia Mancini, Alessandra Ravaioli, Benedetta Vitali, et al.

    Article: Estimates of the burden of skin melanoma in Italy: update to 2024 - Italian Journal of Dermatology and Venereology 2025 Jan 22 - Minerva Medica - Journals

  • Open Access

    Preliminary analysis of the melanoma multimedia educational program for general practitioners on behalf of the Italian melanoma intergroup

    by Federica Zamagni, Fabio Falcini, Serena Magi, Lauro Bucchi, Silvia Mancini, Rosa Vattiato, Emanuele Crocetti, Stefano Falcinelli, Claudio Feliciani, Maurizio Lombardo, et al.

    Introduction. According to the National Oncological Plan 2023-2027 on the importance of multidisciplinary and interactive e-learning training, the Italian Melanoma Intergroup (IMI) has developed MelaMEd (Melanoma Multimedia Education), a national project for general practitioners (GPs) on the prevention and detection of cutaneous melanoma through an online platform and an online course. MelaMEd enables participants to (1) recognize skin lesions that require specialist dermatological assessment, (2) select patients at high risk of melanoma and (3) be informed of the diagnosis and treatment pathway of patients with melanoma. Methods. A free online platform and online course were developed and launched in June 2022. Before starting the course, enrolled participants fill out a pre-training questionnaire concerning the basic knowledge of the disease and the recognition and management of suspicious lesions. After the course, participants will fill out the same questionnaire again. The online course will end in December 2023. Here we present a preliminary analysis of the pre-training results (January 2023-July 2023). The data have been analyzed descriptively. Results. So far, five healthcare centers have participated in the project for a total of 1320 participants. Of these, 298 compiled the pre-training questionnaire. Forty-seven percent of them were aged <40 years. Respondents were almost divided between GPs (47%) and resident GPs (48%). Among the theoretical questions, the “ABCDE” rule and “ugly duckling” sign are well known (96% and 91% of correct answers, respectively), but a lower percentage (68%) of respondents knows the “EFG” rule for the recognition of nodular melanomas and the statement of Breslow thickness (29%). Regarding the series of clinical images of pigmented skin lesions and their management, the percentages rate of accuracy varied from 33% to 87%: melanoma (5 cases) ranges from 36% to 71%, melanocytic nevi (3 cases) from 33% to 84%, whereas the percentages rate of referral for dermatological evaluation varied from 44% to 99%. Melanoma cases referred to dermatologist ranges from 67% to 99%. Conclusions. This preliminary analysis on pre-training questionnaire mainly showed a lack of knowledge of the two major points of melanoma diagnosis (EFG) and management (Breslow thickness), as well as a low rate of participants. We will compare the proportions of correct answers to the questionnaires before and after the course once available.